HSV 1716

Drug Profile

HSV 1716

Alternative Names: Herpes simplex virus 1716 - Virttu; HSV1716; Oncolytic HSV-1716; Seprehvir

Latest Information Update: 23 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crusade Laboratories
  • Developer Cincinnati Childrens Hospital Medical Center; Pediatric Brain Tumor Consortium; Virttu Biologics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Glioblastoma; Glioma; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Preclinical Prostate cancer

Most Recent Events

  • 17 Nov 2015 Interim pharmacodynamics data from a preclinical trial in Prostate cancer released by Virttu Biologics
  • 09 Nov 2015 pharmacodynamics data from a preclinical study in Cancer presented at the 106th Annual Meeting of the American Association for Cancer Research (AACR-2015)
  • 05 Nov 2015 Preclinical trials in Prostate cancer in United Kingdom (IV) prior to November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top